Lassa virus glycoprotein (GPC) (LASV GPC)

The Lassa virus glycoprotein (GPC) is the primary surface protein of the Lassa virus (LASV), the causative agent of Lassa fever (UniProt P08669). It is a type I transmembrane glycoprotein that exists as a trimer on the viral envelope and is synthesized as a precursor cleaved by the host protease SKI-1/S1P into two subunits: GP1 and GP2. GP1 mediates binding to host cell receptors such as alpha-dystroglycan, while GP2 facilitates pH-dependent membrane fusion within the endosome (PubMed 28834718). As the sole target for neutralizing antibodies, GPC is the central focus for vaccine development and the design of antiviral entry inhibitors. Therapeutic strategies targeting GPC include small molecule inhibitors like LHF-535 (PubMed 28533438) and ST-193 (PubMed 23135244), as well as monoclonal antibody cocktails like Arevirumab. Understanding the structural dynamics of the GPC trimer is critical for developing effective countermeasures against this high-consequence pathogen (PubChem AID 1259343).

Other names

Lassa virus envelope glycoproteinLASV GPCGP1 subunitGP2 subunitLassa virus spike proteinBiotinylated Lassa virus glycoprotein peptides – MBP fusion protein

Inhibition of viral entry by blocking receptor binding (GP1) or preventing pH-dependent membrane fusion (GP2).